Montelukast effect in patients with chronic obstructive pulmonary disease
Phase 4
- Conditions
- Chronic Obstructive Pulmonary Disease.Other chronic obstructive pulmonary disease
- Registration Number
- IRCT20190423043361N1
- Lead Sponsor
- Khoram-Abad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 74
Inclusion Criteria
COPD patients
aged 40 to 70 years
Patients with stable conditions in the last trimester
Patients who are at stages II-III-IV of the disease
Exclusion Criteria
History of hospitalization
History of long-term Corticosteroid use
Other inflammatory diseases such as cardiovascular, rheumatic, pulmonary, and liver disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TNF-a level. Timepoint: 60 days. Method of measurement: ELISA Diagnostic Kits.;Level of IL-18. Timepoint: 60 days. Method of measurement: ELISA Diagnostic Kits.;Levels of CRP. Timepoint: 60 days. Method of measurement: semiquantitative C-reactive protein latex agglutination kit.
- Secondary Outcome Measures
Name Time Method